Press Release : FDA grants Breakthrough Therapy -2-

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] Cancer.Net. Myelodysplastic Syndromes - MDS: Statistics. [Internet; cited July 2021]. Available from: https://www.globenewswire.com/Tracker?data=Q_ifbRfhYFMhZ5ZbsEpznu4NubQUrcggrL0G0edOkIRCN8EZZiVKVLHSi3mzSknRjoqln6yiy2C0O671HIjNy5XuXVWG6yAph5u3zMnSUeKPkQLtD1sgunJxYCvvUnnGDqKDFuAZ8gjlG0w5y9UuHSXaiicTkdpLbT8Ea3hwswd0OXaLNyoxByK44iilEQYqa0Tp2E8YwhgSKJ0saGkp5_7F8k-1dxB2jm_7K2qI_t4= https://www.cancer.net/cancer-types/myelodysplastic-syndromes-mds/statistics

[2] American Cancer Society. What Are Myelodysplastic Syndromes? [Internet; cited July 2021]. Available from: https://www.globenewswire.com/Tracker?data=Q_ifbRfhYFMhZ5ZbsEpznp3r8vTIMAw6Mc5sXKxAf8NloRbPuI4cuPocDvlG-Dznj4x2cvtkc8Z4RAKBg-OCSh6VHEXifKD17-n87nASCDGGGmgoNAvCzQZuudUiEYELvgpz144Hvd-8Vl-IMP05WfoI9XVhCef5CRCg6qE8sqr0fA57WDlX3eJdHY_YzXjqfbbbznYPgw5SKIq6aqzcN_bPY03nd7Sg1ERQSIHsr39Yhfj13fo_t9a0MHPNSrV8 https://www.cancer.org/cancer/myelodysplastic-syndrome/about/what-is-mds.html

[3] Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32(5):691-8.

[4] Catenacci DV, Schiller GJ. Myelodysplastic syndromes: a comprehensive review. Blood Rev. 2005;19(6):301-19.

[5] American Cancer Society. Survival Statistics for Myelodysplastic Syndromes [Internet; cited July 2021]. Available from: https://www.globenewswire.com/Tracker?data=Q_ifbRfhYFMhZ5ZbsEpznp3r8vTIMAw6Mc5sXKxAf8NloRbPuI4cuPocDvlG-Dznj4x2cvtkc8Z4RAKBg-OCSmWr36Mtru8kjV5tN0cRKihRjPuycl0bp5Jlirx0pwwyEeO_lRxWA4adiueJQdlS0stKvKlZsL_s37e23u7jF3WxVhQ24OH43qM219quLUbV8gJM3VXpEadmvvmotub5LS1c6x9aWXU4LFqtGCoYlmihRJumKR4_AXZfLh0wfmbTeOIJn6IGXsAhJaKLH7P3LJ3_XA-Z73zkY1NhBFz0URI= https://www.cancer.org/cancer/myelodysplastic-syndrome/detection-diagnosis-staging/survival.html

[6] Center for Drug Evaluation and Research. Medical Review(s): Azacitidine: Application 50-794 (part 2) Silver Spring, MD: FDA; 2004 [Internet; cited July 2021]. Available from: https://www.globenewswire.com/Tracker?data=Q_ifbRfhYFMhZ5ZbsEpznrSS6rPnLshiN4M6std12XEnRA7Jk59CTJUW6gB_0bQ98pGXt1bbZZCephNqR1XPlWgniBy2szdbBXrnaXpj3JU9aKqPiI3VnG4rMleA93vxzdO_NlWAx5koOtkctX_AY-vi1JC0MzOK9931XkvkAeE9AJ2UyADJFIAm5TQ5hrCTxMoCyyfQOLJSZ4V_i5OyiCcuB_hzmhGNfpE-rVSuBSiwn5TasDUN9YWTBMOKAzhy https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-794_Vidaza_Medr_P2.pdf

[7] Leukemia & Lymphoma Society. The International Prognostic Scoring System. [Internet; cited July 2021]. Available from: https://www.globenewswire.com/Tracker?data=Q_ifbRfhYFMhZ5ZbsEpznrAVK1KW_Ry2wCmzNNYYSWzWn7ABzNFuyI70Ivnc_Og-2ncNTVLFmo5605CXASKcdoB6Mswi47SDiW9qLUy347YtCicmiQPCWdZSKYaqpBShuajx2UJmO4MpQffM1JSEsu4qLa6VAkBRtNoOm_SdyLaz-B8h9g4cZi3UZq2T2DUsH6Mxxdw34lVa0eFFyHOBDO6tGwtFPHs6pJIcs7DVDj1aq3BNK98hk4zI5XCOApwVbUnWQgO7aH8TrVPGKQWx1tA2-3BtlloK7UeKXkKlkpE= https://www.lls.org/myelodysplastic-syndromes/diagnosis/international-prognostic-scoring-system

[8] Kantar Health. Treatment architecture: United States myelodysplastic syndromes. 2015. CancerMPact.

Roche Group Media Relations

Phone: [phone] / e-mail: https://www.globenewswire.com/Tracker?data=m1S1JR46GMaqpl2PPZCXlhyWnuI4CUtfHkZQDci2Z9Z5W0uHJwafHmSq2in_6U_AuSHWXbCZ7njnJgiaa6nArzLgCwS-FsvyrxDiw6zFC49-6VxzAZL-9CT9MiDhnhnZ [e-mail]

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: [phone] 
 e-mail: mailto:[e-mail] 
 [e-mail] 
-------------------------------------------- 
 

Attachment

   -- 210721_MR_Venclexta FDA BTD_EN 
      https://ml-eu.globenewswire.com/Resource/Download/29c72f1b-074d-4784-b5b9-b097a6e97062

(END) Dow Jones Newswires

July 21, 2021 01:00 ET (05:00 GMT)